Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Neoplasm Recurrence, Local 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 4Etoposide 2veliparib 1sagopilone 1sacituzumab govitecan 1pomalidomide 1pembrolizumab 1etoposide phosphate 1Topotecan 1Tomography, X-Ray Computed 1Temozolomide 1Rhenium 1Radiation 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Penfluridol 1Pemetrexed 1PT-100 dipeptide 1Histamine Antagonists 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Small Cell × Rhenium × Clear all
NCT00100256 2022-11-07

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Andarix Pharmaceuticals

Phase 1/2 Unknown
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡